New

Drugs for Rheumatoid Arthritis Professional Market

2021

Drugs for Rheumatoid Arthritis Professional Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Molecule (Pharmaceuticals, Biopharmaceuticals); Route Of Administration (Oral, Parenteral)

| Report Code: TIPRE00021890 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Drugs for Rheumatoid Arthritis Professional Market 2028 By Therapeutic Molecule, Route Of Administration | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Rheumatoid arthritis is a chronic inflammatory disorder that cause joint pain. Over long periods of time, the inflammation can cause bone erosion and joint deformity.

MARKET DYNAMICS

The drugs for rheumatoid arthritis professional market is driving due to rise in incidence of rheumatoid arthritis and upsurge in geriatric population. However, higher cost of biologics & biosimilars are expected to hamper the growth of the global drugs for rheumatoid arthritis professional market. Moreover, increasing pipeline is anticipated to drive demand the growth of the market.

MARKET SCOPE

The "Drugs for Rheumatoid Arthritis Professional Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Drugs for Rheumatoid Arthritis Professional market with detailed market segmentation by therapeutic molecule and route of administration. The Drugs for Rheumatoid Arthritis Professional market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Drugs for Rheumatoid Arthritis Professional market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The drugs for rheumatoid arthritis professional market is segmented on the basis by therapeutic molecule and route of administration. Based on therapeutic molecule, the market is categorized as pharmaceuticals, biopharmaceuticals. Pharmaceuticals segment is further segmented into NSAIDs, analgesics, DMARDs and corticosteroids. Biopharmaceuticals segment is further segmented into biologics and biosimilars. Based on route of administration, the market is categorized oral and parenteral.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Drugs for Rheumatoid Arthritis Professional market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Drugs for Rheumatoid Arthritis Professional market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Drugs for Rheumatoid Arthritis Professional market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the Drugs for Rheumatoid Arthritis Professional market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Drugs for Rheumatoid Arthritis Professional market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Drugs for Rheumatoid Arthritis Professional market are anticipated to have lucrative growth opportunities in the future with the rising demand for Drugs for Rheumatoid Arthritis Professional market in the global market. Below mentioned is the list of few companies engaged in the Drugs for Rheumatoid Arthritis Professional market.

The report also includes the profiles of key players in Drugs for Rheumatoid Arthritis Professional market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   AbbVie Inc.
  •   Boehringer Ingelheim GmbH
  •   Novartis AG
  •   Regeneron Pharmaceuticals, Inc.
  •   Pfizer, Inc.
  •   Johnson & Johnsons Services, Inc
  •   Bristol-Myers Squibb Company
  •   F. Hoffmann-La Roche Ltd.
  •   Celegene Corporations
  •   MedImmune, LLC

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Drugs For Rheumatoid Arthritis Professional Market - By Therapeutic Molecule
1.3.2 Drugs For Rheumatoid Arthritis Professional Market - By Route Of Administration
1.3.3 Drugs For Rheumatoid Arthritis Professional Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET - GLOBAL MARKET ANALYSIS
6.1. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL - GLOBAL MARKET OVERVIEW
6.2. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC MOLECULE
7.1. OVERVIEW
7.2. THERAPEUTIC MOLECULE MARKET FORECASTS AND ANALYSIS
7.3. PHARMACEUTICALS
7.3.1. Overview
7.3.2. Pharmaceuticals Market Forecast and Analysis
7.3.3. NSAIDs Market
7.3.3.1. Overview
7.3.3.2. NSAIDs Market Forecast and Analysis
7.3.4. analgesics Market
7.3.4.1. Overview
7.3.4.2. analgesics Market Forecast and Analysis
7.3.5. DMARDs Market
7.3.5.1. Overview
7.3.5.2. DMARDs Market Forecast and Analysis
7.3.6. Corticosteroids Market
7.3.6.1. Overview
7.3.6.2. Corticosteroids Market Forecast and Analysis
7.4. BIOPHARMACEUTICALS
7.4.1. Overview
7.4.2. Biopharmaceuticals Market Forecast and Analysis
7.4.3. Biologics Market
7.4.3.1. Overview
7.4.3.2. Biologics Market Forecast and Analysis
7.4.4. Biosimilars Market
7.4.4.1. Overview
7.4.4.2. Biosimilars Market Forecast and Analysis
8. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. PARENTERAL
8.4.1. Overview
8.4.2. Parenteral Market Forecast and Analysis
9. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Drugs For Rheumatoid Arthritis Professional Market Overview
9.1.2 North America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis
9.1.3 North America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Therapeutic Molecule
9.1.4 North America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Route Of Administration
9.1.5 North America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Countries
9.1.5.1 United States Drugs For Rheumatoid Arthritis Professional Market
9.1.5.1.1 United States Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.1.5.1.2 United States Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.1.5.2 Canada Drugs For Rheumatoid Arthritis Professional Market
9.1.5.2.1 Canada Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.1.5.2.2 Canada Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.1.5.3 Mexico Drugs For Rheumatoid Arthritis Professional Market
9.1.5.3.1 Mexico Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.1.5.3.2 Mexico Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.2. EUROPE
9.2.1 Europe Drugs For Rheumatoid Arthritis Professional Market Overview
9.2.2 Europe Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis
9.2.3 Europe Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Therapeutic Molecule
9.2.4 Europe Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Route Of Administration
9.2.5 Europe Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Drugs For Rheumatoid Arthritis Professional Market
9.2.5.1.1 Germany Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.2.5.1.2 Germany Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.2.5.2 France Drugs For Rheumatoid Arthritis Professional Market
9.2.5.2.1 France Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.2.5.2.2 France Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.2.5.3 Italy Drugs For Rheumatoid Arthritis Professional Market
9.2.5.3.1 Italy Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.2.5.3.2 Italy Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.2.5.4 Spain Drugs For Rheumatoid Arthritis Professional Market
9.2.5.4.1 Spain Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.2.5.4.2 Spain Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.2.5.5 United Kingdom Drugs For Rheumatoid Arthritis Professional Market
9.2.5.5.1 United Kingdom Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.2.5.5.2 United Kingdom Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.2.5.6 Rest of Europe Drugs For Rheumatoid Arthritis Professional Market
9.2.5.6.1 Rest of Europe Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.2.5.6.2 Rest of Europe Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market Overview
9.3.2 Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis
9.3.3 Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Therapeutic Molecule
9.3.4 Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Route Of Administration
9.3.5 Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Drugs For Rheumatoid Arthritis Professional Market
9.3.5.1.1 Australia Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.3.5.1.2 Australia Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.3.5.2 China Drugs For Rheumatoid Arthritis Professional Market
9.3.5.2.1 China Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.3.5.2.2 China Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.3.5.3 India Drugs For Rheumatoid Arthritis Professional Market
9.3.5.3.1 India Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.3.5.3.2 India Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.3.5.4 Japan Drugs For Rheumatoid Arthritis Professional Market
9.3.5.4.1 Japan Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.3.5.4.2 Japan Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.3.5.5 South Korea Drugs For Rheumatoid Arthritis Professional Market
9.3.5.5.1 South Korea Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.3.5.5.2 South Korea Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.3.5.6 Rest of Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market
9.3.5.6.1 Rest of Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.3.5.6.2 Rest of Asia-Pacific Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market Overview
9.4.2 Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis
9.4.3 Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Therapeutic Molecule
9.4.4 Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Route Of Administration
9.4.5 Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Drugs For Rheumatoid Arthritis Professional Market
9.4.5.1.1 South Africa Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.4.5.1.2 South Africa Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.4.5.2 Saudi Arabia Drugs For Rheumatoid Arthritis Professional Market
9.4.5.2.1 Saudi Arabia Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.4.5.2.2 Saudi Arabia Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.4.5.3 U.A.E Drugs For Rheumatoid Arthritis Professional Market
9.4.5.3.1 U.A.E Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.4.5.3.2 U.A.E Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.4.5.4 Rest of Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market
9.4.5.4.1 Rest of Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.4.5.4.2 Rest of Middle East and Africa Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Drugs For Rheumatoid Arthritis Professional Market Overview
9.5.2 South and Central America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis
9.5.3 South and Central America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Therapeutic Molecule
9.5.4 South and Central America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Route Of Administration
9.5.5 South and Central America Drugs For Rheumatoid Arthritis Professional Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Drugs For Rheumatoid Arthritis Professional Market
9.5.5.1.1 Brazil Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.5.5.1.2 Brazil Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.5.5.2 Argentina Drugs For Rheumatoid Arthritis Professional Market
9.5.5.2.1 Argentina Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.5.5.2.2 Argentina Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
9.5.5.3 Rest of South and Central America Drugs For Rheumatoid Arthritis Professional Market
9.5.5.3.1 Rest of South and Central America Drugs For Rheumatoid Arthritis Professional Market by Therapeutic Molecule
9.5.5.3.2 Rest of South and Central America Drugs For Rheumatoid Arthritis Professional Market by Route Of Administration
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. DRUGS FOR RHEUMATOID ARTHRITIS PROFESSIONAL MARKET, KEY COMPANY PROFILES
12.1. ABBVIE INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BOEHRINGER INGELHEIM GMBH
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. REGENERON PHARMACEUTICALS, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER, INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. JOHNSON AND JOHNSONS SERVICES, INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BRISTOL-MYERS SQUIBB COMPANY
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. F. HOFFMANN-LA ROCHE LTD.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. CELEGENE CORPORATIONS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MEDIMMUNE, LLC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. AbbVie Inc.
2. Boehringer Ingelheim GmbH
3. Novartis AG
4. Regeneron Pharmaceuticals, Inc.
5. Pfizer, Inc.
6. Johnson & Johnsons Services, Inc
7. Bristol-Myers Squibb Company
8. F. Hoffmann-La Roche Ltd.
9. Celegene Corporations
10. MedImmune, LLC
TIPRE00021890
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.